59 results about "Alfacalcidol" patented technology

The invention discloses an alfacalcidol dispersible tablet and a preparation method of the alfacalcidol dispersible tablet. The alfacalcidol dispersible tablet is prepared from an alfacalcidol clathrate compound and a preparation supplementary material, wherein the preparation supplementary material comprises a filling agent, a disintegrating agent, a diluting agent, a lubricating agent, a flow aid and a flavouring agent; and the alfacalcidol clathrate compound is prepared by carrying out clathration on alfacalcidol and 2,6-dimethyl-Beta-cyclodextrin based on the molar ratio of 4: 1 to 0.5: 3. The alfacalcidol dispersible tablet has the advantages of being quick to dissolve out, fast to absorb, high in bioavailability, excellent in stability, convenient to take, etc.

The invention discloses alfacalcidol capsules and a preparation method of the alfacalcidol capsules. The alfacalcidol capsules comprise alfacalcidol and formulation excipients, wherein the formulation excipients comprise a filler, a disintegrant, a surfactant, a diluent, a lubricant, a glidant and a flavoring agent. The alfacalcidol capsules disclosed by the invention have the advantages of quickness in dissolution, fastness in absorption, high bioavailability, good stability and convenience in taking.

The invention relates to a preparation method for a compound, in particular to the preparation method for separating and purifying alfacalcidol. Aiming at the deficiencies of the conventional preparation technology, the invention provides a novel method for preparing alfacalcidol with good yield and high purity. The preparation method comprises the steps as follows: taking vitamin D3 as a raw material; removing most of trans-isomer impurities generated after chemical reaction by utilizing Diels-Alder reaction; and refining and purifying by preparative high pressure liquid chromatography to prepare high-purity alfacalcidol. According to the preparation method, the reaction conditions are moderate, the yield is high, and the purity of alfacalcidol reaches up to 99.5%.

The present invention relates to medicine technology, and is especially one kind of oral solution containing alfacalcidol. The oral solution contains: alfacalcidol in therapeutically effective amount, therapeutically acceptable organic acid supplementary material in such amount as to regulate the pH value of the or al solution to 2.0-4.0, and water. The oral solution containing alfacalcidol has high stability.

The invention relates to a medicament for treating degenerative osteopathy, which mainly comprises the following raw materials by mass: 20 to 60 kilograms of compound bone collagen, 20 to 60 kilograms of glucosamine, 0.05 to 1.0 kilogram of Alfacalcidol, 3 to 30 kilograms of soy isoflavones, 3 to 30 kilograms of vitamin C calcium, 10 to 60 kilograms of cane sugar, 1 to 20 kilograms of dextrin, 1 to 20 kilograms of high-expansion type carboxyrnethyl starch sodium, 0.5 to 10 kilograms of magnesium stearate and 5 to 50 kilograms of silicon dioxide. The invention also provides a method for preparing the medicament.

The invention discloses an alfacalcidol sustained-release capsule and a preparation method thereof. The alfacalcidol sustained-release capsule disclosed by the invention is prepared through filling an alfacalcidol sustained-release pellet in a capsule shell; and during preparation, the alfacalcidol sustained-release pellet is obtained through coating a drug-containing layer and a coating layer outside a blank pellet core and then filled in the capsule shell, thereby obtaining the alfacalcidol sustained-release capsule. According to the alfacalcidol sustained-release capsule and the preparation method of the alfacalcidol sustained-release capsule, the drug release is uniform, the aims of long acting and curative effect improving can be reached, and the dosage can be reduced while the same drug action is maintained, so that side effects to patients caused by drug taking are reduced; and the preparation method is simple, the quality of obtained products is stable, and thus, the method is applicable to large-scale production application.

The invention relates to an alfacalcidol soft capsule and a preparation method thereof. The contents of the alfacalcidol soft capsule comprise the following components in parts by weight: 85-125 partsof oily substrate, 0.01-0.2 part of antioxidant and 0.000001-0.000015 part of alfacalcidol, wherein the oily substrate is midchain triglyceride fatty acid. The preparation method comprises the following steps: (1) mixing antioxidant with a part of oily substrate to obtain a mixture; (2) pouring the rest oily substrate into a liquid preparation tank, and then adding the mixture acquired in step (1) into the liquid preparation tank, stirring and uniformly mixing; (3) placing the tank in a dark place, adding alfacalcidol into the liquid preparation tank, and uniformly stirring and mixing under the atmosphere of protective gas to obtain contents of the alfacalcidol soft capsule; (4) preparing the contents into the soft capsule in a dark place. The alfacalcidol soft capsule is high in stability.

The invention relates to a soft alfacalcidol capsule and a preparation method thereof. The content of the soft capsule is prepared from the following ingredients in parts by weight: 35-50 parts of alfacalcidol, 15-20 parts of glycerinum, 20-40 parts of polyethylene glycol 4000, 10-20 parts of polyethylene glycol 6000, 10-20 parts of an accelerant, 45-57 parts of a thickener and 30-60 parts of an antioxygen. The preparation method improves the content of active ingredients in the preparation and reduces medicine dose; by adding specific ingredients including the glycerinum, polyethylene glycol 4000 and polyethylene glycol 6000, the stability and bioavailability of the soft capsule are effectively improved; the preparation formulation of conventional alfacalcidol preparations is successfully changed, so that alfacalcidol can be better taken and absorbed by patients.

The invention discloses a high performance liquid chromatography method for alfacalcidol tablet related substances. A sample solution and a control solution are obtained by adopting octadecylsilane bonded silica as a filler and an acetonitrile-water mixed solution as a mobile phase, adopting an ultraviolet detector for a wavelength of 265 nm and especially adopting a vortex-extraction-concentration way, so the detection of an extremely low dose of a drug in the above tablet and related substances thereof is greatly ensured. The method be used to simultaneously analyze all known impurities in the alfacalcidol tablet, and allows the content of each known impurity to be effectively controlled by a main component self-contrasted technology with a correction factor, the resolution among all impurity peaks and the resolution between a main peak and the adjacent impurity peak are respectively greater than 1.5, and the peak purities of the main peak and all the impurity peaks are respectivelymore than 1.0. The high performance liquid chromatography method is a simple and reliable analysis method for the quality control of the alfacalcidol tablet.

The invention discloses an alfacalcidol powder and a preparation method thereof. The alfacalcidol powder is prepared from the following ingredients in parts by weight: 5-8 parts of alfacalcidol, 15-20 parts of polyvinylpyrrolidone, 60-70 parts of starch, 60-70 parts of powdered sugar, 10-15 parts of microcrystalline cellulose and 5-8 parts of aerosil. The preparation method has the benefits that the content of alfacalcidol in the preparation is increased and the medicine dose for patients is decreased; with the addition of the polyvinylpyrrolidone, the bioavailability and stability of the alfacalcidol powder are increased and the clinical effect is remarkable.

The invention provides an alfacalcidol derivative and a preparation method thereof. The molecular structural formula is as follows, wherein R is selected from the follows. According to the alfacalcidol derivative and the preparation method thereof provided by the invention, vitamin D3 is taken as an initiator and is subjected to 7-step reaction, thereby acquiring a target product. Compared with alfacalcidol, the alfacalcidol derivative has higher water solubility and is more beneficial to clinic application of drugs.

The invention provides a medicine preparation for treating postmenopausal osteoporosis and belongs to the technical field of medicines. The medicine preparation contains alfacalcidol, tibolone and necessary pharmaceutical excipients. The medicine preparation for treating postmenopausal osteoporosis, provided by the invention, has the advantages of good disintegration, good absorbing degree, high bioavailability, quick curing effect and convenience for taking. Pharmacological actions of the alfacalcidol and the tibolone can be taken to a maximum extent, the defect of single preparation in efficacy is compensated, and the medicine preparation is an excellent medicine preparation for treating the postmenopausal osteoporosis.

The invention belongs to the technical field of medicine preparation, and particularly relates to an alfacalcidol soft capsule and a preparation method thereof. The capsule is prepared from a capsuleshell solution and capsule contents, wherein the capsule contents comprise alfacalcidol, medium-chain triglyceride, ascorbyl palmitate, gliadin, polyethylene glycol, phospholipid and glycerol monolaurate; and the capsule shell solution comprises gelatin, glycerol, water, ethylparaben, sodium alginate and chitosan. The preparation method of the alfacalcidol soft capsule is simple, and the preparedalfacalcidol soft capsule is good in stability and bioavailability and suitable for promotion and application.

The invention discloses a pharmaceutical composition of alfacalcidol and its medical application. The pharmaceutical composition of alfacalcidol provided by the invention contains alfacalcidol and a kind of The natural product compound (Ⅰ) with a novel structure, when alfacalcidol and compound (Ⅰ) act alone, can interfere with myocardial fibrosis in rats with renovascular hypertension by reducing the concentration of collagen; When pyridoxol and compound (I) act in combination, the intervention effect is better, and it can be developed into a drug for preventing and treating myocardial fibrosis in patients with renovascular hypertension, which has outstanding substantive features and significant progress compared with the prior art.

An eczema treatment method comprises application of a therapeutically effective composition in the form of an aqueous topical cream to an affected area of an exterior skin region of a patient, the aqueous topical cream comprising water, a water-soluble organic liquid, a surface active agent, and vitamin D₃ compound or another claimed analog thereof, the vitamin D₃ compound or the analog constituting at least approximately 10 international units per gram (IU/gram), and, most preferably at least approximately 400 IU/gram. An eczema treatment composition comprises a therapeutically effective formulation comprising at least approximately 50%-90% water, between approximately 1-5% PEG-40 stearate, between approximately 1-5% steareth-2, and cholecalciferal at a concentration of at least approximately 50 international units per gram (IU/g) of composition, and, most preferably at least approximately 400 IU/g. A topical vitamin D cream for therapeutic treatment of eczema includes vitamin D or an analog thereof chosen from the group consisting of cholecalciferol, alfacalcidol, calcifedol, and ergocalciferol; water; a water-soluble organic liquid; and a surface active agent, the vitamin D or analog being in a concentration of at least approximately 50 international units per gram (IU/g) of cream. Remarkably, relief from eczema conditions occurs immediately or in less than 3 days.

The invention discloses an alfacalcidol oral liposome drug and a preparation method and application thereof. The alfacalcidol oral liposome drug is prepared from the following raw materials in parts by weight: 1 part of alfacalcidol, 5-50 parts of phospholipid, 1-10 parts of cholesterol and 1-5 parts of an antioxidant. Alfacalcidol is encapsulated by liposome so that the chemical stability of alfacalcidol can be improved, the alfacalcidol can be protected from being damaged by gastric juice, bile, digestive enzymes and other substances through liposome, and the stability of the alfacalcidol ingastrointestinal tracts can be improved, so that absorption and bioavailability of the alfacalcidol in small intestines are improved; and compared with commercially available alfacalcidol tablets, the oral alfacalcidol lipidosome drug has high blood drug level and improved bioavailability, and the treatment effect on osteoporosis is improved.

The invention relates to a method for separating chiral compounds by using molecular sieves, in particular to a separation method of calcitriol, alfacalcidol and esomeprazole sodium. Aiming at overcoming the defects of the existing separation technique, the invention provides a new method for separating the chiral compounds, which has the advantages of high yield and higher purity. By using different molecular sieves, chiral isomer impurities which are produced during preparation can be separated and removed. The method for separating chiral compounds by using molecular sieves has the advantages that the simple is simple and feasible, the pollution is small and the method is suitable for mass production.

The invention discloses a non-coenzyme-dependent enzymatic synthesis method for synthesizing calcitriol through oxidase hydroxylation, and 1, 25-dihydroxy vitamin D3 (calcitriol) which can be used as an intermediate or a raw material medicine of various medicines is directly prepared from alpha calcitriol through a one-pot one-step method. The preparation process is simple and convenient, the yield is high, the downstream treatment process is simple, and no other solvent or cofactor is used except water and acetone (or other organic cosolvents) in the preparation process. The method is a green biosynthesis method and has relatively high atom economy and step economy.

The invention provides an alfacalcidol precursor preparation method. According to the method, an alfacalcidol precursor is prepared through high-temperature water bath reflux, and is separated and purified through high performance liquid chromatography, the structure of the alfacalcidol precursor is identified through HRMS and NMR, and the result shows that the obtained compound is the alfacalcidol precursor. According to the invention, the method is simple in process, short in period, low in cost, high in yield and capable of achieving cyclic preparation.